Ecogenetics: From ecology to health

Toxicology and Industrial Health

Volumn 13, Issue 3, 1997, Pages 163-192

  Nebert, Daniel W ^a   Carvan, Michael J ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Ah receptor; alcohol dehydrogenase; aldehyde dehydrogenase; debrisoquine polymorphism; dioxin; drug metabolizing enzymes; glucose 6 phosphate dehydrogenase; methyltransferase; multiplex phenotype; N acetylation; thiopurine

Indexed keywords

ACYLTRANSFERASE; ALDEHYDE DEHYDROGENASE; AROMATIC HYDROCARBON RECEPTOR; ARYLESTERASE; CYTOCHROME P450; DEBRISOQUINE; DRUG METABOLIZING ENZYME; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; ISONIAZID; MERCAPTOPURINE; OXYGENASE; PHENYLTHIOUREA; THIOPURINE METHYLTRANSFERASE;

ACETYLATOR PHENOTYPE; CANCER; CARCINOGENESIS; CONFERENCE PAPER; DRUG METABOLISM; ENVIRONMENT; ENZYME DEFICIENCY; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; HUMAN GENETICS;

ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HEALTH; ENVIRONMENTAL ILLNESS; HUMANS; INDIVIDUALITY; PEDIGREE; POLYMORPHISM, GENETIC;

EID: 0030925031     PISSN: 07482337     EISSN: None     Source Type: Journal    
DOI: 10.1177/074823379701300205     Document Type: Article

References (59)

1. Bale, A.E., Nebert, D.W., and McBride, O.W. (1987). “Subchromosomal localization of the dioxin-inducible P,450 locus (CYP1) and description of two RFLPs detected with a 3’ P 1450 cDNA probe.” Cytogenet. Cell. Genet. 46:574-575.
2. Brown, A.W.A. (1960). “Mechanisms against resistance against insecticides.” Annu. Rev. Entomol. 5:301-29.
3. Butler, M.A., Lang, N.P., Young, J.F., Caporaso, N.E., Vineis, P., Hayes, R.B., et al. (1992). “Determination of CYP1A2 and acetyltransferase phenotype in human populations by analysis of caffeine urinary metabolites.” Pharmacogenetics 2:116-127.
4. Cairns, J.C., Overbaugh, J., and Miller, S. (1988). “The origin of mutants.” Nature 335:142-145.
5. Caporaso, N., Landi, M.T., and Vineis, P. (1991). “Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence.” Pharmacogenetics 1:4-19.
6. Chang, C.Y., Smith, D.R., Prasad, V.S., Sidman, C.L., Nebert, D.W., and Puga, A. (1993). “Ten nucleotide differences, five of which cause amino acid changes, are responsible for the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice.” Pharmacogenetics 3:312-321.
7. Chapela, I.H., Rehner, S.A., Schultz, T.R., and Mueller, U.G. (1994). “Evolutionary history of the symbiosis between fungus-growing ants and their fungi.” Science 266:1691-1694.
8. Daly, A.K., Cholerton, S., Armstrong, M., and Idle, J.R. (1994). “Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.” Environ. Health Perspect. 102, Suppl. 9:55-61.
9. Dover, G.A. (1986). “Molecular drive in multigene families: How biological novelties arise, spread and are assimilated.” Trends Genet. 2:159-165.
10. Dziuk, L.J. and Plapp, F.W., JR. (1973). “Insecticide resistance in mosquitofish from Texas.” Bull. Environ. Contam. Toxicol. 9:5-19.
11. Endler, J.A. “Variations in the appearance of guppy color patterns to guppies and their predators under different visual conditions.” Visual Res. 31:587-608.
12. Eshleman, A.J. and Murray, T.F. (1991). “Pyrethroid insecticides indirectly inhibit GABA-dependent 36Cl- influx in synaptoneurosomes from the trout brain.” Neuropharmacol. 30:1333-1341.
13. Fernandez-Salguero, P., Pineau, T., Hilbert, D.M., McPhail, T., Lee, S.S.T., Kimura, S., Nebert, D.W., Rudikoff, S., Ward, J.M., and Gonzalez, F.J. (1995). “Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor.” Science 268:722-726.
14. Ffrench-Constant, R.H. (1993). “Cloning of the Drosophila cyclodiene insecticide resistance gene: a novel GABAA receptor subtype?” Comp. Biochem. Physiol. 104C:9-12.
15. Ffrench-Constant, R.H., Steichen, J.C., Rocheleau, T.A., Aronstein, K., and Roush, R.T. (1993). “A single-amino acid substitution in a -aminobutyric acid subtype A receptor locus is associated with cyclodiene insecticide resistance in Drosophila populations.” Proc. Natl. Acad. Sci. USA 90:1957-1961.
16. Fujii-Kuriyama, Y., Ema, M., Matsushita, N., and Sogawa, K. (1995). “Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene.” Pharmacogenetics 5:S149-S153.
17. Goedde, H.W. and Agarwal, D.P. (1986). “Aldehyde oxidation: ethnic variations in metabolism and response.” In: Ethnic Differences in Reactions to Drugs and Xenobiotics. (W. Kalow, H.W. Goedde, D.P. Agarwal, eds.) Alan R. Liss, New York, NY. pp. 113–138.
18. Gonzalez, F.J. and Idle, J.R. (1994). “Pharmacogenetic phenotyping and genotyping: Present status and future potential.” Clin. Pharmacokinet 26:59-70.
19. Gonzalez, F.J. and Nebert, D.W. (1990). “Evolution of the P450 gene superfamily: Animal-plant ‘warfare,’ molecular drive, and human genetic differences in drug oxidation” Trends Genet. 6:182-186.
20. Hankinson, O. (1995). “The aryl hydrocarbon receptor complex.” Annu. Rev. Pharmacol. Toxicol. 35:307-340.
21. Hayashi, S., Watanabe, J., and Kawajiri, K. (1992). “High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and mu-class glutathione S-transferase genes.” Jpn. J. Cancer Res. 83:866-870.
22. Higuchi, S., Parrish, K.M., Dufour, M.C., Towle, L.H., and Harford, T.C. (1992). “The relationship between three subtypes of the flushing response and DSM-III alcohol abuse in Japanese.” J. Stud. Alcohol. 53:553-560.
23. Humbert, R., Adler, D.A., Disteche, C.M., Hassett, C., Omiecinski, C.J., and Furlong, C.E. (1993). “The molecular basis of the human serum paraoxonase activity polymorphism.” Nature Genet. 3:73-76.
24. Idle, J.R. (1991). “Is environmental carcinogenesis modulated by host polymorphism?” Mutat. Res. 247:259-266.
25. Kalow, W. (1992). “Pharmacoanthropology and the genetics of drug metabolism.” In: Pharmacogenetics of Drug Metabolism. (W. Kalow, ed.) Pergamon Press, New York, NY. pp. 865–877.
26. Kalow, W., and Bertilsson, L. (1994). “Interethnic factors affecting drug response.” Advanc. Drug Res. 25:1-53.
27. Kingman, S. (1995). “Does a CF gene confer a hidden advantage?” J. N.I.H. Res. 7:34-35.
28. Kouri, R.E., McKinney, C.E., Slomiany, D.J., Snodgrass, D.R., Wray, N.P., and McLemore, T.L. (1982). Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes Cancer Res. 42:5030-5037.
29. Krynetski, E., Tai, H.L., Yates, C.R., Fessing, M., Loennechen, T., Schuetz, J.D., et al. “Genetic polymorphism of thiopurine s-methyltransferase: clinical importance and molecular mechanisms.” Pharmacogenetics 6. (In press)
30. Lander, E. and Schork, N.J. (1994). “Genetic dissection of complex traits.” Science 265:2037-2048.
31. Lewalter, J. and Korallus, U. (1985). “Blood protein conjugates and acetylation of aromatic amines.” Int. Arch. Occup. Environ. Health. 56:179-196.
32. Liang, H.C., Li, H., McKinnon, R.A., Duffy, J.J., Potter, S.S., et al. (1996). “CYP1A2(-/-) null mutant mice develop normally, but show altered drug metabolism.” Proc. Natl. Acad. Sci. USA 93:1671-1676.
33. Nebert, D.W. (1979). “Multiple forms of inducible drug-metabolizing enzymes. A reasonable mechanism by which any organism can cope with adversity.” Mol. Cell. Biochem. 27:27-46.
34. Nebert, D.W. (1989). “The AH locus: genetic differences in toxicity, cancer, mutation, and birth defects.” Crit. Rev. Toxicol. 20:153-174.
35. Nebert, D.W. (1991). “Role of genetics and drug metabolism in human cancer risk.” Mutat. Res. 247:267-281.
36. Nebert, D.W. (1994). “Drug-metabolizing enzymes in ligand-modulated transcription.” Biochem. Pharmacol. 47:25-37.
37. Nebert, D.W. and Gonzalez, F.J. (1987). “P450 genes and evolutionary genetics.” Hosp. Practice 22:63-74.
38. Nebert, D.W., McKinnon, R.A., and Puga, A. (1996). “Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer.” DNA Cell. Biol. 15:273-280.
39. Nebert, D.W., Petersen, D.D., and Puga, A. (1991). “Human AH locus polymorphism and cancer: Inducibility of CYP1A1 and other genes by combustion products and dioxin.” Pharmacogenetics 1:68-78.
40. Nebert, D.W., Puga, A., and Vasiliou, V. (1993). “Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer and in signal transduction.” Ann. NY Acad. Sci. 685:624-640.
41. Nebert, D.W. and Weber, W.W. (1990). “Pharmacogenetics.” In: Principles of Drug Action. The Basis of Pharmacology, 3rd ed. (W.B. Pratt, P.W. Taylor, eds.) Churchill Livingstone Inc., New York, NY. pp. 469–531.
42. Nei, M. and Saitou, N. (1986). “Genetic relationship of human populations and ethnic differences in reaction to drugs and food.” In: Ethnic differences in reactions to drugs and xenobiotics. (W. Kalow, H.W. Goedde, D.P. Agarwal, eds.) Alan R. Liss, New York, NY. pp. 21–37.
43. Passera, L., Roncin, E., Kaufmann, B., and Keller, L. (1996). “Increased soldier production in ant colonies exposed to intraspecific competition.” Nature 379:630-631.
44. Pelkonen, O. and Nebert, D.W. (1982). “Metabolism of polycyclic hydrocarbons: etiologic role in carcinogenesis.” Pharmacol. Rev. 34:189-222.
45. Pineau, T., Fernandez-Salguero, P., Lee, S.T.T., McPhail, T., Ward, J.M., and Gonzalez, F.J. (1995). “Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 CYP1A2.” Proc. Natl. Acad. Sci. USA 92:5134-5138.
46. Plapp, F.W., JR (1981). “Toxicity of synthetic pyrethroids to laboratory and field populations of the tobacco budworm in central Texas.” J. Econ. Entomol. 74:201-209.
47. Plapp, F.W. JR, and Wang, T.C. (1983). “Genetic origins of insecticide resistance.” In: Pest Resistance to Pesticides. (G.P. Georghiou, T. Saito, eds.) Plenum Publishing Corp., New York, NY. pp. 47–70.
48. Price-Evans, D.A. (1992). “N-acetyltransferase.” In: Pharmacogenetics of drug metabolism. (W. Kalow, ed.) Pergamon Press, New York, NY. pp. 95–178.
49. Rotter, J.I. and Diamond, J.M. (1987). “What maintains the frequencies of human genetic diseases?” Nature 329:289-290.
50. Safe, S. (1990). “Polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs): Biochemistry, toxicology and mechanisms of action.” Toxicol. 21:51-88.
51. Swanson, H.I. and Bradfield, C.A. (1993). “The AH receptor: genetics, structure and function.” Pharmacogenetics 3:213-230.
52. Tang, B.K., Zhou, Y., and Kalow, W. (1994). “Caffeine as a probe for CYP1A2 activity: Potential influence of renal factors on urinary phenotypic trait measurements.” Pharmacogenetics 4:117-124.
53. Travisano, M., Mongold, J.A., Bennett, A.F., and Lenski, R.E. (1995). “Experimental tests of the roles of adaptation, chance, and history in evolution.” Science 267:87-90.
54. Vasiliou, V., Weiner, H., Marselos, M., and Nebert, D.W. (1995). “Mammalian aldehyde dehydrogenase genes: classification based on evolution, structure and regulation.” Eur. J. Drug Metab. Pharmacokin. 20:53-64.
55. Vatsis, K.P., Weber, W.W., Bell, D.A., Dupret, J.M., Price-Evans, D.A., Grant, D.M., et al. (1995). “Nomenclature for N-acetyltransferases.” Pharmacogenetics 5:1-17.
56. Vogel, F. and Motulsky, A.G. (1986). Human Genetics Springer-Verlag. Berlin, Germany.
57. Whitlock, J.P., JR (1991). “Genetic and molecular aspects of 2,3,7,8-tetrachlorodibenzo-p-dioxin action.” Annu. Rev. Pharmacol. Toxicol. 30:251-277.
58. Yarbrough, J.D., Roush, R.T., Bonner, J.C., and Wise, D.A. (1986). “Monogenic inheritance of cyclodiene insecticide resistance in mosquitofish, Gambusia affinis.” Experientia 42:851-853.
59. Yue, Q.Y., Svensson, J.O., Alm, C., Sjoqvist, F., and Säwe, J. (1989). “Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.” Br. J. Clin. Pharmacol. 28:629-637.